Zydus Cadila Covid Vaccine

Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.

Zydus Cadila's Covid vaccine ZyCoV-D will initially be used in 7 states, including Maharashtra, Tamil Nadu, UP and Bengal, which have been recommended to identify the districts with a high number of people who have not received a single dose yet.

The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received emergency use authorisation from the drug regulator on August 20.

Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above

The government today said Zydus Cadila's indigenously-developed needle-free Covid vaccine ZyCoV-D will be introduced in the nationwide vaccination drive very shortly and will be differentially priced than the jabs being used currently.

Preparations are on to make Zydus Cadila's COVID-19 DNA vaccine available to people and although the price is a "clear issue", a decision will be taken soon to make it a part of the country's vaccination programme, the government said on Thursday.

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

There will be more clarity on the prices of COVID-19 vaccine ZyCOV-D by next week, Zydus Group Managing Director Dr Sharvil Patel said today.

Zydus Cadila, whose Covid vaccine ZyCoV-D for adults and children aged 12 years and above got approval yesterday, said it hopes to produce one crore doses per month by October.

Prime Minister Narendra Modi on Friday hailed it as a "momentous feat" and said the approval to the world's first DNA-based vaccine against the coronavirus is a testimony to the innovative zeal of India's scientists.

Zydus Cadila's Covid vaccine ZyCoV-D, meant for adults and children aged 12 years and above, was today approved for "restricted use in emergency situation" by the Central Drugs Standard Control Organisation (CDSCO).

India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.

Cadila Healthcare's total revenue from operations in the first quarter of the current fiscal stood at Rs 4,025.4 crore, compared to Rs 3,514.6 crore in the year-ago period

Drugs Controller General of India (DCGI) is examining pharmaceutical major Zydus Cadila's COVID-19 vaccine for children, said Dr VK Paul, Member-Health, Niti Aayog on Friday.

Zydus Cadila has requested emergency use approval for its ZyCoV-D three-dose Covid shot that is the "world's first Plasmid DNA vaccine". The shot is "needle-free", says the company, and "safe for children".

Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.

Zydus Cadila's Covid vaccine ZyCoV-D will initially be used in 7 states, including Maharashtra, Tamil Nadu, UP and Bengal, which have been recommended to identify the districts with a high number of people who have not received a single dose yet.

The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received emergency use authorisation from the drug regulator on August 20.

Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above

The government today said Zydus Cadila's indigenously-developed needle-free Covid vaccine ZyCoV-D will be introduced in the nationwide vaccination drive very shortly and will be differentially priced than the jabs being used currently.

Preparations are on to make Zydus Cadila's COVID-19 DNA vaccine available to people and although the price is a "clear issue", a decision will be taken soon to make it a part of the country's vaccination programme, the government said on Thursday.

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

There will be more clarity on the prices of COVID-19 vaccine ZyCOV-D by next week, Zydus Group Managing Director Dr Sharvil Patel said today.

Zydus Cadila, whose Covid vaccine ZyCoV-D for adults and children aged 12 years and above got approval yesterday, said it hopes to produce one crore doses per month by October.

Prime Minister Narendra Modi on Friday hailed it as a "momentous feat" and said the approval to the world's first DNA-based vaccine against the coronavirus is a testimony to the innovative zeal of India's scientists.

Zydus Cadila's Covid vaccine ZyCoV-D, meant for adults and children aged 12 years and above, was today approved for "restricted use in emergency situation" by the Central Drugs Standard Control Organisation (CDSCO).

India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.

Cadila Healthcare's total revenue from operations in the first quarter of the current fiscal stood at Rs 4,025.4 crore, compared to Rs 3,514.6 crore in the year-ago period

Drugs Controller General of India (DCGI) is examining pharmaceutical major Zydus Cadila's COVID-19 vaccine for children, said Dr VK Paul, Member-Health, Niti Aayog on Friday.

Zydus Cadila has requested emergency use approval for its ZyCoV-D three-dose Covid shot that is the "world's first Plasmid DNA vaccine". The shot is "needle-free", says the company, and "safe for children".